计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| B414218-5mg |
5mg |
期货 ![]() |
| |
| B414218-25mg |
25mg |
现货 ![]() |
| |
| B414218-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | AKOS040741291 | s8847 | N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-5-fluoro-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzamide | Orludodstat | N-(2-Chloro-6-fluorophenyl)-4-(4-ethyl-4,5-dihydro-3-(hydr |
|---|---|
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | BAY 2402234 |
| 生化机理 | BAY 2402234 是一种新型的选择性二氢烟酸脱氢酶(DHODH)抑制剂,其 IC50 为 1.2\u2009nM。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 二氢烟酸脱氢酶(醌)抑制剂 |
| 产品介绍 |
Information BAY 2402234 BAY 2402234 is a novel and selective dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 1.2 nM. Targets DHODH (Cell-free assay) 1.2 nM In vitro BAY 2402234 induces differentiation and inhibits proliferation in AML cell lines across multiple AML subtypes. In vivo BAY 2402234 shows strong monotherapy efficacy and induces differentiation in AML xenograft models in vivo. Cell Research(from reference) Cell lines:MOLM-13, HEL, MV4-11, SKM-1 and THP-1 cell lines Concentrations:0.1nM to 1μM Incubation Time:96 h |
| 纯度 | ≥99% |
| ALogP | 4.103 |
|---|---|
| hba_count | 4 |
| HBD Count | 2 |
| Rotatable Bond | 8 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504773160 |
|---|---|
| 分子类型 | 未知 |
| IIUPAC Name | N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo-1,2,4-triazol-1-yl]-5-fluoro-2-[(2S)-1,1,1-trifluoropropan-2-yl]oxybenzamide |
| INCHI | 1S/C21H18ClF5N4O4/c1-3-30-17(9-32)29-31(20(30)34)15-8-16(35-10(2)21(25,26)27)11(7-14(15)24)19(33)28-18-12(22)5-4-6-13(18)23/h4-8,10,32H,3,9H2,1-2H3,(H,28,33)/t10-/m0/s1 |
| InChi Key | KNVJMHHAXCPZHF-JTQLQIEISA-N |
| Smiles | CCN1C(=NN(C1=O)C2=C(C=C(C(=C2)OC(C)C(F)(F)F)C(=O)NC3=C(C=CC=C3Cl)F)F)CO |
| Isomeric SMILES | CCN1C(=NN(C1=O)C2=C(C=C(C(=C2)O[C@@H](C)C(F)(F)F)C(=O)NC3=C(C=CC=C3Cl)F)F)CO |
| 分子量 | 520.84 |
| Reaxy-Rn | 37174574 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=37174574&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 100 mg/mL (191.99 mM); Ethanol: 33 mg/mL (63.35 mM); Water: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 100 |
| DMSO(mM) Max Solubility | 191.997542431457 |
| Water(mg / mL) Max Solubility | <1 |
| 分子量 | 520.799 g/mol |
| XLogP3 | 4.000 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 10 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 520.094 Da |
| 单同位素质量Monoisotopic Mass | 520.094 Da |
| 拓扑极表面积Topological Polar Surface Area | 94.500 Ų |
| 重原子数Heavy Atom Count | 35 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 819.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 |
| 1. Wu D, Wang W, Chen W, Lian F, Lang L, Huang Y, Xu Y, Zhang N, Chen Y, Liu M et al.. (2018) Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells.. Haematologica, 103 (9): (1472-1483). [PMID:29880605] |
| 2. Sykes DB. (2018) The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia.. Expert Opin Ther Targets, 22 (11): (893-898). [PMID:30318938] |
| 3. Christian S, Merz C, Evans L, Gradl S, Seidel H, Friberg A, Eheim A, Lejeune P, Brzezinka K, Zimmermann K et al.. (2019) The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.. Leukemia, 33 (10): (2403-2415). [PMID:30940908] |